Selective inhibition of transcription of the Ets2 gene in prostate cancer cells by a triplex-forming oligonucleotide.

The transcription factor Ets2 has a role in cancer development and represents an attractive therapeutic target. In this study, we designed a triplex-forming oligonucleotide (TFO) directed to a homopurine:homopyrimidine sequence in the Ets2 promoter. Transcription factors of the Sp family bound to this sequence and mutation of the Sp1 site reduced Ets2 promoter activity. The Ets2-TFO had high binding affinity for the target sequence and inhibited binding of Sp1/Sp3 to the overlapping site. This effect occurred with a high degree of sequence specificity. Mismatched oligonucleotides did not inhibit Sp1/Sp3 binding and mutations in the target sequence that abolished triplex formation prevented inhibition of Sp1/Sp3 binding by the TFO. The Ets2-TFO inhibited Ets2 promoter activity and expression of the endogenous gene in prostate cancer cells at nanomolar concentrations. The TFO did not affect reporter constructs with mutations in the TFO binding site and promoters of non-targeted genes. Expression of non-targeted genes was also not affected in TFO-treated cells. Collectively, these data demonstrated that the anti-transcriptional activity of the Ets2-TFO was sequence- and target-specific, and ruled out alternative, non-triplex mediated mechanisms of action. This anti-transcriptional approach may be useful to examine the effects of selective downregulation of Ets2 expression and may have therapeutic applications.

[1]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[2]  Michael C. Ostrowski,et al.  Rapid phosphorylation of Ets-2 accompanies mitogen-activated protein kinase activation and the induction of heparin-binding epidermal growth factor gene expression by oncogenic Raf-1 , 1997, Molecular and cellular biology.

[3]  C. Catapano,et al.  Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene. , 2000, Biochemistry.

[4]  H. Krutzsch,et al.  Cellular Nucleic Acid Binding Protein Regulates the CT Element of the Human c- myc Protooncogene (*) , 1995, The Journal of Biological Chemistry.

[5]  S. Ross,et al.  The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Roussel,et al.  Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. , 1994, Oncogene.

[7]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[8]  P. Pečinka,et al.  DNA tetraplex formation in the control region of c-myc. , 1998, Nucleic acids research.

[9]  V. Sementchenko,et al.  ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.

[10]  P. Bates,et al.  Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding* , 1999, The Journal of Biological Chemistry.

[11]  F. Quadrifoglio,et al.  Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins. , 1998, European journal of biochemistry.

[12]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[13]  C. F. Bennett,et al.  Progress in antisense oligonucleotide therapeutics. , 1996, Annual review of pharmacology and toxicology.

[14]  R. Cardiff,et al.  A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.

[15]  C. Catapano,et al.  Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene. , 2002, Nucleic acids research.

[16]  P. Hanawalt,et al.  Triple helix-forming oligonucleotides target psoralen adducts to specific chromosomal sequences in human cells. , 1999, Nucleic acids research.

[17]  H. G. Kim,et al.  Inhibition of transcription of the human c-myc protooncogene by intermolecular triplex. , 1998, Biochemistry.

[18]  G. Viglietto,et al.  Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. , 2001, Cancer research.

[19]  R L Vessella,et al.  Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS‐2 in prostate cancer , 1997, The Prostate.

[20]  S. Ritchie,et al.  Transcription of the Human c-Src Promoter Is Dependent on Sp1, a Novel Pyrimidine Binding Factor SPy, and Can Be Inhibited by Triplex-forming Oligonucleotides* , 2000, The Journal of Biological Chemistry.

[21]  B. Wold,et al.  Phosphorothioate oligonucleotide-directed triple helix formation. , 1994, Biochemistry.

[22]  D. Fujita,et al.  Organization and analysis of the promoter region and 5' non-coding exons of the human c-src proto-oncogene. , 1993, Oncogene.

[23]  B. Pettitt,et al.  Binding of triple helix forming oligonucleotides to sites in gene promoters. , 1991, Biochemistry.

[24]  C. Catapano,et al.  Antigene and antiproliferative effects of a c-myc-targeting phosphorothioate triple helix-forming oligonucleotide in human leukemia cells. , 2000, Cancer research.

[25]  B. Aggarwal,et al.  Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. , 1996, Cancer research.

[26]  Winter Ta.  Gene targeted agents: new opportunities for rational drug development. , 2000 .

[27]  Y. Israel,et al.  Inhibition of Gene Expression by Triple Helix Formation in Hepatoma Cells (*) , 1995, The Journal of Biological Chemistry.

[28]  D. Praseuth,et al.  Triple helix formation and the antigene strategy for sequence-specific control of gene expression. , 1999, Biochimica et biophysica acta.

[29]  A. Seth,et al.  The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. , 1990, Oncogene.

[30]  G. Mavrothalassitis,et al.  Positive and negative factors regulate the transcription of the ETS2 gene via an oncogene-responsive-like unit within the ETS2 promoter region. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[31]  Michael C. Ostrowski,et al.  Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2 , 1996, Molecular and cellular biology.

[32]  M. White,et al.  Targeted inhibition of transcription elongation in cells mediated by triplex-forming oligonucleotides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Lyuba Benimetskaya,et al.  Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide , 1997, Nucleic Acids Res..

[34]  P. Glazer,et al.  Specific mutations induced by triplex-forming oligonucleotides in mice. , 2000, Science.

[35]  D. Gilliland.  The diverse role of the ETS family of transcription factors in cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  C. Giovannangeli,et al.  Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Glazer,et al.  Mutagenesis in Mammalian Cells Induced by Triple Helix Formation and Transcription-Coupled Repair , 1996, Science.

[38]  A. Firulli,et al.  DNA triplexes and regulation of the c-myc gene. , 1994, Gene.

[39]  B. Wasylyk,et al.  Reversion of Ras transformed cells by Ets transdominant mutants. , 1994, Oncogene.

[40]  P. Glazer,et al.  Triplex DNA: fundamentals, advances, and potential applications for gene therapy , 1997, Journal of Molecular Medicine.

[41]  G. Mavrothalassitis,et al.  Molecular and functional characterization of the promoter of ETS2, the human c-ets-2 gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[42]  I Lebedeva,et al.  Antisense oligonucleotides: promise and reality. , 2001, Annual review of pharmacology and toxicology.

[43]  G. Mavrothalassitis,et al.  The human ETS-2 gene promoter: molecular dissection and nuclease hypersensitivity. , 1990, Oncogene.

[44]  A. Seth,et al.  c-ets-2 protooncogene has mitogenic and oncogenic activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  C. Hauser,et al.  Oncogenic Ras can induce transcriptional activation through a variety of promoter elements, including tandem c-Ets-2 binding sites. , 1994, Oncogene.